<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 1984 an extensive review of phenylbutazone risks was undertaken by the Food and Drug Administration (FDA) </plain></SENT>
<SENT sid="1" pm="."><plain>Since that review, new recommendations for the drug's use have been published </plain></SENT>
<SENT sid="2" pm="."><plain>Marketed in 1952, phenylbutazone has long been recognized as capable of inducing <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The risk of marrow <z:hpo ids='HP_0000716'>depression</z:hpo> is greatest in elderly females treated for over a month </plain></SENT>
<SENT sid="4" pm="."><plain>Overall, the risk does not exceed that of many commonly used drugs (e.g., <z:chebi fb="93" ids="17334">penicillin</z:chebi>, which induces <z:mp ids='MP_0002531'>anaphylaxis</z:mp>) </plain></SENT>
<SENT sid="5" pm="."><plain>Nonetheless, phenylbutazone should not be a drug of first choice and should not be used for minor, self-limited conditions </plain></SENT>
</text></document>